Argenx announced on July 27, 2026, that it agreed to acquire Forte Biosciences for $2.2 billion in cash. The deal values the Dallas-based biotech at $77 per share, representing a 41% premium to Forte’s closing stock price on the prior Friday. The acquisition is positioned as a step to expand Argenx’s immunology-focused drug pipeline.
The announcement was reported by STAT and written by Andrew Joseph. The source noted Argenx’s corporate footprint and background but did not provide full transaction details such as the expected close date, financing arrangements, or required regulatory approvals.
Argenx has been active in the immunology space and is described in the source as a major success story in that area. The company’s marketed drug Vyvgart has U.S. approvals for the autoimmune conditions generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. STAT reported that Vyvgart has shown steady sales increases as Argenx expanded the drug’s label to cover more patients.
The purchase of Forte is framed as an effort to broaden Argenx’s pipeline of immunology assets. The source linked the deal to a broader trend of acquisitions across biotech, where midsize companies continue to pursue targets to build out portfolios.
According to the source, Argenx will pay $2.2 billion in cash for Forte. The per-share price of $77 equals a 41% premium over Forte’s most recent closing price before the announcement. The source specified that Forte is based in Dallas, Texas, and Argenx has its main operations in Belgium.
No additional financial terms, such as any contingent payments, debt assumptions, or break fees, were reported in the source. The article did not disclose whether the purchase price is expected to be funded with cash on hand, debt, equity, or a combination.
The source described Argenx as a notable success in immunology, citing the performance of Vyvgart and its expanding label. That background frames the acquisition as consistent with Argenx’s strategy to build on its commercial and development momentum in autoimmune diseases.
STAT also placed the transaction within a larger wave of biotech mergers and acquisitions, noting that companies of varying sizes are actively searching for targets. The article referenced an ongoing run of deals in the sector, though it did not provide a complete list of recent transactions or aggregate deal values beyond describing the trend.
The source identified Forte as a Dallas-based biotech and focused the deal narrative on its relevance to autoimmune disease drug development. The article did not detail Forte’s specific product candidates, clinical-stage assets, or ongoing trials. Information on Forte’s pipeline composition, clinical data, or regulatory milestones was not reported in the source.
Several typical acquisition details were not included in the STAT piece as presented in the source material. The article did not report:
Those items may be disclosed in fuller company filings, investor communications, or follow-on reporting.
By paying a 41% premium to Forte’s recent market price, Argenx signaled willingness to invest significantly to add capabilities in immunology. The source framed the move as part of a continued round of midmarket and larger deals across biotech, where companies with marketed products or established commercial traction are acquiring smaller firms to augment pipelines.
Argenx’s existing commercial product, Vyvgart, and its expanding label were cited as part of the rationale for continued pipeline building. Beyond that context, the source did not provide independent analysis of how the acquisition will affect competition in specific autoimmune disease markets or forecasts for Argenx’s revenue or R&D spending.
The source announced the agreement and the headline transaction figures. It did not report a closing date, regulatory review expectations, or planned operational changes. STAT’s article was behind a subscription prompt for full access; the available excerpt provided the core terms but not the complete set of statements or disclosures that commonly accompany such deals.
Readers seeking more detail should look for the companies’ official press releases, securities filings, or follow-up reporting that may include management commentary, exact closing conditions, and descriptions of the assets acquired. The source did not include those specifics in the portion of the story provided.
This story was reported by Andrew Joseph and published by STAT on July 27, 2026. The source material used here was the STAT article as specified; additional particulars beyond the cash price, per-share valuation, premium, company locations, and the background on Vyvgart were not available in the supplied text.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.